Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iconovo ABOSTO:ICO +5.26%34 Cash Ratio is 3.70 as of Mar. 2026, which is 14% above its 10-year median of 3.25. GuruFocus rates OSTO:ICO with a GF Score™ of 34/100 and a GF Value™ of kr0.26 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Iconovo AB ranks better than 81.07% on this metric.
Iconovo AB has a Cash Ratio of 3.70. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Iconovo AB's Cash Ratio or its related term are showing as below:
OSTO:ICO'
s Cash Ratio Range Over the Past 10 Years
Min: 0.55 Med: 3.25 Max: 17.98
Current: 3.7
During the past 10 years, Iconovo AB's highest Cash Ratio was 17.98. The lowest was 0.55. And the median was 3.25.
OSTO:ICO's Cash Ratio is ranked better than 81.07% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 0.975
vs OSTO:ICO: 3.70
Iconovo AB (OSTO:ICO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Iconovo AB Cash Ratio Related Terms
Iconovo AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Iconovo AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Iconovo AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iconovo AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Iconovo AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Iconovo AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iconovo AB (OSTO:ICO) has a Cash Ratio of 3.70 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Iconovo AB and its competitors. This is 14% above median its historical median of 3.25. Over the past decade, Iconovo AB's Cash Ratio has ranged from 0.55 to 17.98. According to the industry distribution chart, Iconovo AB ranks #159 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Iconovo AB's Cash Ratio too high?
Iconovo AB's current Cash Ratio of 3.70 is 14% above median its 10-year median of 3.25. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 17.98. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Iconovo AB's value of 3.70 is 279.5% above this industry median. Based on the distribution chart, Iconovo AB ranks #159 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Iconovo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Iconovo AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Iconovo AB ranks #159 out of 840 companies for Cash Ratio. This places Iconovo AB in the top 19% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.98. Iconovo AB's value of 3.70 is 279.5% above this benchmark. Historically, Iconovo AB's own Cash Ratio has ranged from 0.55 to 17.98 over the past decade. While the company's 10-year median is 3.25 vs. the industry median of 0.98, Iconovo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iconovo AB's current Cash Ratio of 3.70 is 279.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Iconovo AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iconovo AB's current Cash Ratio is 3.70, which is 14% above median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iconovo AB stock overvalued right now?
Based on GuruFocus' analysis, Iconovo AB (OSTO:ICO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.26, compared to a current price of kr1.00 — trading 284.6% above its estimated fair value. The current Cash Ratio is 3.70, which is 14% above median its 10-year median of 3.25 and 279.5% above the Medical Devices & Instruments industry median of 0.98. Iconovo AB's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Iconovo AB (OSTO:ICO), the current Cash Ratio is 3.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iconovo AB (OSTO:ICO) Overvalued in 2026?
Based on GuruFocus' analysis, Iconovo AB stock appears to be overvalued.
The current stock price of kr1.00 is trading 284.6% above its estimated GF Value™ of kr0.26.
GuruFocus considers Iconovo AB to be Significantly Overvalued.
Key valuation signals for OSTO:ICO:
Cash Ratio: 3.70 (14% above median its 10-year median of 3.25)
GF Value™: kr0.26 vs. price of kr1.00 (284.6% above fair value)
Industry Position: 279.5% above the Medical Devices & Instruments median (#159 of 840)
No single metric tells the full story. See the OSTO:ICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
34GF Score
Get the complete analysis for OSTO:ICO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ICO has been successfully added to your 
